Why the study?
Does macitentan prevent right ventricular remodeling better than bosentan in a rat model of non-vasoreactive pulmonary hypertension?
Population
Bleomycin-treated rat model of non-vasoreactive pulmonary hypertension
Comparison
Macitentan (100 mg·kg(-1)·d(-1)) vs Bosentan (300 mg·kg(-1)·d(-1))
Design
Preclinical
Authors
Loading...
Hypothesis-generating for macitentan in experimental PH; leaves open clinical translation and should not change practice.
Does macitentan prevent right ventricular remodeling better than bosentan in a rat model of non-vasoreactive pulmonary hypertension?
Macitentan demonstrated superior efficacy to bosentan in preventing pulmonary and right ventricular hypertrophy in a rat model of non-vasoreactive pulmonary hypertension, potentially due to greater tissue distribution.
Iglarz et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: